X
Disease breathalyser firm Owlstone appoints ‘serial entrepreneur’ to board
https://pharmaphorum.com/news/disease-breathalyser-firm-owlstone-appoints-serial-entrepreneur-to-board/
diagnostics
Breath Biopsy company adds new investor to $15m fundraising
Owlstone Medical, the innovative company which promises to revolutionise the diagnosis of cancer by simply analysing a patient’s breath has been given a major funding boost.
The future of diagnostics: personal genetic services
With genetic analysis and diagnostic tests now available via mail order, how will this trend towards the proactive consumer impact the evolution of health management?
Angle produces new data backing liquid biopsy in cancer
Angle hopes Parsortix will be first approved cell-based liquid biopsy.
Major trial for potential ‘game changer’ cancer diagnostic begins
Breath Biopsy will be tested in its ability to detect several cancers earlier than traditional methods.
Angle poised to take on US cancer diagnostics market
Circulating tumour cell test could help select drug therapy.
Theranos settles with investor on claims it lied about business
Partner Fund Management agrees to drop lawsuits.
‘Repeated violations’ behind Theranos lab closure
CMS report describes failures meeting its own quality control procedures.
